Menu
Cart 0
Bronchopulmonary Dysplasia Pipeline Analysis 2018

Bronchopulmonary Dysplasia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • $2,400.00
  • Publishing Date: February 2018
  • Format: PDF
Sample Request

Bronchopulmonary Dysplasia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Bronchopulmonary Dysplasia (BPD) Analysis report covers 6 drugs currently in different phases of development.  Bronchopulmonary Dysplasia (BPD) is a chronic respiratory disease affecting preature newborns and infants. BPD generally occurs in severely ill infants eho have been on ventilator or have received oxygen for long period of time. Symptoms of BPD are cyanosis, constant and persistent cough, rapid and shallow breathing and shortness of breath. BP is diagnosed using chest x-ray, blood tests, Pulse oximetry and echocardiography. Currently medications such as bronchodilators (Albuterol, to open up airways), Diuretics (to reduce fluid build-up in the lungs) and anti-inflammatory are used for the treatment of the disease.

The report provides Bronchopulmonary Dysplasia (BPD) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report Airway Therapeutics, LLC, Medipost Co., Ltd, Meridigen Biotechnology, Shire Plc, Therabron Therapeutics and United Therapeutics Corporation.

Scope:

  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Airway Therapeutics, LLC
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Medipost Co., Ltd.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Meridigen Biotechnology
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Shire Plc
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Therabron Therapeutics
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. United Therapeutics Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
List of Tables
List of Figures

Related Reports
Back to the top